Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia

Area of Science:

• Obstetrics and Gynecology
• Proteomics
• Biomarker Discovery

Background:

• Preeclampsia is a serious pregnancy complication that is currently unpredictable in first-time mothers.
• Accurate prediction of preeclampsia is crucial for improving antenatal care and maternal outcomes.

Purpose of the Study:

• To identify novel protein biomarkers for predicting preeclampsia in healthy nulliparous women.
• To develop and validate predictive models for preeclampsia using a multi-step approach.

Main Methods:

• A 3-step mass spectrometry workflow was used to discover and validate protein biomarkers.
• Candidate biomarkers were quantified in plasma from independent cohorts (SCOPE study and European cohort).
• Logistic regression analysis identified multimarker models predicting preeclampsia with specific sensitivity and positive predictive value.

Main Results:

• Eight validated multimarker models were developed, detecting 50-56% of preeclampsia cases.
• These models achieved an 80% detection rate for preterm preeclampsia.
• Key biomarkers include insulin-like growth factor acid labile subunit and soluble endoglin, supplemented by other markers and blood pressure.

Conclusions:

• Biomarker combinations, particularly those involving insulin-like growth factor acid labile subunit, show significant potential for preeclampsia prediction.
• Validated models offer a promising tool for transforming antenatal care in healthy nulliparous pregnancies.
• The predictive performance was consistent when using ELISA for key biomarker measurements.